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Identification of the fructose 
transporter GLUT5 (SLC2A5) as a 
novel target of nuclear receptor 
LXR
Irene Zwarts1, Tim van Zutphen1, Janine K. Kruit1, Weilin Liu1, Maaike H. Oosterveer1, 
Henkjan J. Verkade1, N. Henriette Uhlenhaut  2,3 & Johan W. Jonker1
Fructose has become a major constituent of our modern diet and is implicated as an underlying cause 
in the development of metabolic diseases. The fructose transporter GLUT5 (SLC2A5) is required for 
intestinal fructose absorption. GLUT5 expression is induced in the intestine and skeletal muscle of type 
2 diabetes (T2D) patients and in certain cancers that are dependent on fructose metabolism, indicating 
that modulation of GLUT5 levels could have potential in the treatment of these diseases. Using an 
unbiased screen for transcriptional control of the human GLUT5 promoter we identified a strong and 
specific regulation by liver X receptor α (LXRα, NR1H3). Using promoter truncations and site-directed 
mutagenesis we identified a functional LXR response element (LXRE) in the human GLUT5 promoter, 
located at −385 bp relative to the transcriptional start site (TSS). Finally, mice treated with LXR agonist 
T0901317 showed an increase in Glut5 mRNA and protein levels in duodenum and adipose tissue, 
underscoring the in vivo relevance of its regulation by LXR. Together, our findings show that LXRα 
regulates GLUT5 in mice and humans. As a ligand-activated transcription factor, LXRα might provide 
novel pharmacologic strategies for the selective modulation of GLUT5 activity in the treatment of 
metabolic disease as well as cancer.
The increasing prevalence of obesity is cause for public health concern since it is a major risk factor for the 
development of chronic metabolic diseases including type 2 diabetes (T2D), cardiovascular disease and certain 
types of cancer. The obesity pandemic is primarily attributed to our modern lifestyle of excessive calorie intake 
and relative inactivity. Fructose may be an important contributor to this pandemic as excessive consumption 
of fructose but not glucose has been shown to increase visceral adiposity and insulin resistance in overweight/
obese humans1. In addition, fructose consumption has dramatically increased in the past 50 years to more than 
10% of our daily calorie intake, mainly in the form of sucrose and inexpensive corn-based sweeteners such as 
high-fructose corn syrup (HFCS) that were introduced in the early 1970’s2–4.
Because of differences in absorption and metabolism between fructose and glucose, they have unique effects 
on the development of specific features of the metabolic syndrome. For example, whereas glucose is used as a 
fuel by all cells in the body and its plasma levels are tightly controlled by insulin, fructose is mainly taken up and 
metabolized by the intestine and liver, independently of insulin. In addition, since fructose doesn’t stimulate 
secretion of insulin, leptin or other satiety hormones, it is a much weaker suppressor of appetite than glucose1,5–7. 
In the liver, glucose is metabolized via phosphofructokinase (PFK), a rate-limiting step in the glycolytic pathway 
and subject to strong feedback inhibition. Fructose, on the other hand, can bypass this PFK regulatory block 
via fructokinase or ketohexokinase (KHK), allowing continued glycolytic flux independent of cellular energy 
status. This uncontrolled hepatic fructose metabolism increases lipogenesis and, consequently the development 
of non-alcoholic fatty liver disease (NAFLD)7,8. Another consequence of this lack in feedback regulation of fruc-
tolysis is a rapid depletion of ATP, resulting in increased uric acid production (hyperuricemia). Hyperuricemia 
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in turn is known to cause hypertension and gout but is also an independent risk factor for metabolic syndrome, 
cardiovascular disease and the development of chronic kidney disease (CKD)9.
Besides the deleterious metabolic effects of fructose, its intestinal malabsorption, also known as dietary 
fructose intolerance, is a common problem, particularly in babies and patients with gastrointestinal disorders. 
Incomplete fructose absorption from the small intestine causes bloating, abdominal pain and diarrhea due to bac-
terial fructose fermentation in the colon10,11. Acute feeding studies have shown that almost one third of patients 
with irritable bowel syndrome (IBS) suffer from fructose malabsorption and benefit from a fructose-restricted 
diet12,13.
Fructose transport is mediated by members of the GLUT-family of facilitated sugar transporters encoded by 
the solute carrier family 2A (SLC2A) genes, which are essential for intestinal fructose absorption and fructose 
metabolism (Reviewed in14). GLUT5 (SLC2A5) is a high-affinity fructose transporter primarily expressed at the 
apical surface of intestinal epithelial cells but also at lower levels in testis, kidney, brain, skeletal muscle and white 
adipose tissue (WAT)15. GLUT5 is the only GLUT-member that has exclusive affinity for fructose and is essential 
for first-pass intestinal fructose absorption and generation of fructose-induced hypertension based on studies 
using Glut5 deficient mice16. The main inducers of GLUT5 expression are fructose and to a lesser extent glu-
cose, yet the underlying molecular mechanism of regulation by these sugars is largely unknown. Fructose trans-
port from the intestine to the blood and uptake by the liver is mediated by GLUT2 (SLC2A2), a high-capacity, 
glucose-dependent fructose co-transporter primarily localized on the basolateral membrane of enterocytes and 
hepatocytes.
Under normal conditions, intestinal GLUT5 expression is low in neonates, explaining their sensitivity to 
fructose malabsorption, but in experiments with rats it has been shown that its expression can be induced by 
thyroid hormone (triiodothyronine, T3) and glucocorticoids through activation of the thyroid hormone receptor 
(THR) and the glucocorticoid receptor (GR), respectively, both members of the nuclear receptor (NR) family of 
ligand-activated transcription factors17,18. Whereas GLUT5 expression was confirmed to be regulated by THR 
activation in vitro, T3 treatment in vivo only increased intestinal Glut5 mRNA in rat pups younger than 22 days, 
suggesting that T3 has a role in intestinal maturation18–20. The intestine of neonatal rats was also sensitized to 
fructose-induced GLUT5 expression by the corticosteroid and GR ligand dexamethasone17,21.
Under pathophysiological conditions, GLUT5 expression was shown to be upregulated in the intestine and in 
skeletal muscle of T2D patients, and this could be reversed in skeletal muscle by treatment with pioglitazone, an 
insulin sensitizing drug of the thiazolidinedione (TZD) class of anti-diabetic drugs22,23. Moreover, GLUT5 expres-
sion is also overexpressed in certain cancers that are highly dependent on fructose uptake and metabolism such as 
breast cancer24,25, acute myeloid leukemia26 and pancreatic cancer metastasis27, providing cancer cells a route to 
increase the energy delivery in order to match increased energy demand caused by uncontrolled proliferation28,29. 
Despite recent focus on the impact of fructose on metabolic homeostasis and cancer, the regulatory mechanisms 
involved are still poorly understood.
In the current study, we identified the sterol-responsive NR liver x receptor α (LXRα) as a novel transcrip-
tional regulator of both human and mouse GLUT5. Here we characterized the response element in the human 
GLUT5 promoter, responsible for the interaction with LXRα and investigated in mice treated with a specific 
agonist how LXR-activation affects GLUT5 expression in vivo.
Results
Promoter regulation of the human fructose transporter GLUT5 by LXRα. Using a luciferase 
reporter screen for the transcriptional regulation by ligand-activated members of the NR-family that heterod-
imerize with RXR, we observed a strong and specific regulation of the human GLUT5 promoter (−900/+3 bp 
relative to the transcription start site) by thyroid hormone receptors THRα and -β and LXRα in CV-1 cells 
(Fig. 1a). The regulation of the human GLUT5 promoter by THRα and -β has previously been described19. RXRα, 
the heterodimeric partner of THR, alone did not result in a significant increase in luciferase signal, neither in the 
presence or absence of its ligand 9-cis-Retinoic acid (9cRA, 1 µM) (Fig. 1b). THRs are known to act as transcrip-
tional repressors in the absence of their ligand, thyroid hormone (T3). Indeed, co-transfection of THRα together 
with RXRα resulted in an approximately 80% repression of the GLUT5 promoter activity, in the absence of T3 
(Fig. 1b)30. In the presence of T3 (1 μM), THRs act as transcriptional activators and in line with this we observed 
an about 7-fold increased GLUT5 promoter activity by either THRα or -β as compared to basal promoter activity 
(Fig. 1b).
The regulation of GLUT5 by LXR has not been reported previously. Co-transfection of LXRα together with 
its heterodimeric partner RXRα resulted in an activation of about 6-fold, which could be further stimulated to 
about 12-fold by addition of the synthetic LXR ligand T0901317 (T09) with an optimal concentration of 1 µM 
(Fig. 1c,d). In contrast, LXRβ/RXRα was less potent and resulted only in an about 3-fold activation of the GLUT5 
promoter, and this could not be further increased by the addition of T09 (Fig. 1c). The regulation of GLUT5 by 
LXRα was not specific to CV-1 cells as we also observed this in HEK293AD cells (Fig. S2). Together, these results 
demonstrate that LXRα is a strong and specific transcriptional regulator of the human GLUT5 gene.
Identification of functional LXR-responsive DR4 element in the human GLUT5 promoter. Next, 
we investigated the mechanism by which LXRα regulates the human GLUT5 promoter. By in silico promoter 
analysis using MatInspector (Genomatix) to predict putative transcription factor binding sites, we identified 4 
putative LXR response elements (LXREs) consisting of direct repeats of the consensus hexanucleotide sequence 
AGGTCA with a spacing of 4 (DR4) in the 900 bp human GLUT5 promoter. To localize the essential DR4 element 
for the regulation by LXR, we generated three promoter truncations spanning −783 bp, −429 bp and −374 bp 
to +3 bp, respectively of the hGLUT5 promoter sequence and cloned these in the pGL4-luc reporter plasmid 
(Fig. 2a). Whereas responsiveness to LXR activation was retained in the −783/+3 and −429/+3 truncations, 
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this was almost completely abolished in the −374/+3 truncation. Based on these results, we conclude that the 
DR4 element essential for the regulation by LXRα is located within the promoter region between −429 and 
−374 bp (Fig. 2b). To further investigate the binding of LXR to this element we mutated both hexanucleo-
tide repeats of this DR4 using site-directed mutagenesis, resulting in a change of sequence from the wild-type 
5′-TGCCCTCAGATTACCT-3′ to mutant 5′-TcCaaTCAGATTcagT-3′. Similar to the −374/+3 truncation, 
activation by LXR was completely abolished in this mutant, indicating that this DR4 located on −385 bp indeed 
functions as a bona fide LXRE (Fig. 2b). Interestingly, this binding site has previously been described as a Thyroid 
hormone receptor response element (TRE)19. Indeed, in the −374/+3 promoter truncation and the mutated DR4 
GLUT5 promoter, also the THR regulation was abolished (Fig. 2b). To further investigate this regulation, we 
performed a competitive reporter assay and showed that LXRα and THRβ interfere with each other’s ability to 
activate the reporter, suggesting that both nuclear receptors compete for binding (Fig. S3).
Regulation of the mouse Glut5 promoter by LXRα. Sequence alignment of the human, mouse and rat 
proximal GLUT5 promoters (500 bp upstream of the ATG start codon) showed a 66% similarity between human 
and rodent (mouse or rat), and a 87% similarity between mouse and rat Glut5 promoters (Fig. S4a). To determine 
whether the regulation of the human GLUT5 promoter by LXR is conserved in mice, we cloned the mouse Glut5 
promoter into the pGL4-luc reporter plasmid. Since the mouse Glut5 gene is alternatively transcribed in somatic 
and germ cells, we cloned the sequence −1014 bp to +3 bp relative to the ATG start codon, as described for 
somatic cells31.
Co-transfection of the mouse Glut5 reporter construct with LXRα/RXRα expression plasmids resulted in an 
approximately 3-fold induction of luciferase activity and this was only slightly further stimulated by T09, both in 
CV-1 cells (Fig. 3) and in HEK293AD cells (Fig. S2). This induction was isoform-specific, as it was not observed 
for LXRβ. In addition, treatment with 1 μM 9cRA in the presence of RXRα resulted in an about 2-fold induction 
of the promoter activity, highlighting the role of RXR activation in mouse Glut5 transcriptional regulation. Unlike 
Figure 1. Transcriptional regulation of the human GLUT5 promoter by nuclear receptors LXR and THR. 
Luciferase reporter analysis of the hGLUT5 promoter for regulation by (a) Nuclear Receptors heterodimerizing 
with RXR; (b) THRα, THRβ; (c) LXRα and LXRβ. CV-1 cells were co-transfected with the proximal human 
GLUT5 promoter (−900/+3 bp) and expression plasmids for the different NRs in combination with equal 
amounts of heterodimeric partner RXRα. Y-axis indicates luciferase activity relative to LacZ and normalized 
to the basal hGLUT5 promoter activity. Ligand-dependent activation of THR and LXR was tested by addition 
of T3 (1 μM) or T09 (1 μM), respectively, at 24 h after transfection. (d) Dose-dependent stimulation of LXRα-
mediated hGLUT5 promoter regulation by LXR ligand T0901317.
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hGLUT5, mGlut5 did not appear to be substantially regulated by THRα or –β, either in the presence or absence 
of T3, although a small (<2-fold) increase was observed for THRβ (Fig. 3). The genomic binding of LXRα to the 
GLUT5 promoter was supported by publicly available chromatin immunoprecipitation sequencing (ChIP-seq) 
data in primary mouse macrophages (Gene Transcription Regulation Database, http://gtrd.biouml.org), in which 
an LXR binding site was identified at 1765 bp upstream of the Glut5 transcription start site (TSS) for germ cells. A 
second LXR binding site was identified at 155 bp upstream of the TSS for somatic cells (Fig. S4b). Together, these 
results show that the regulation of the GLUT5 promoter by LXR is conserved between humans and rodents and 
indicate that the mouse can be used as a model to study this process.
Figure 2. Identification of the functional LXR-responsive element in the human GLUT5 promoter. (a) 
Overview of the promoter truncations used to localize the functional LXRE in the proximal human GLUT5 
promoter (−900/+3 bp). Predicted LXREs are represented by green boxes. The red box represents a site-
directed point mutation in the functional LXRE. (b) Luciferase reporter analysis of the hGLUT5 promoter 
truncations and mutant for regulation by LXR and THR. CV-1 cells were co-transfected with the indicated 
hGLUT5-luc constructs and expression plasmids for LXRα or THRα in combination with equal amounts of 
heterodimeric partner RXRα. X-axis indicates luciferase activity relative to LacZ and normalized to the negative 
control (NC = basal hGLUT5 promoter activity). Ligand-dependent activation of LXR and THR was tested by 
addition of T09 (1 μM) or T3 (1 μM), respectively, at 24 h after transfection. For statistics, different truncations/
mutations were compared for each receptor in the presence of ligand.
Figure 3. Transcriptional regulation of the mouse Glut5 promoter by nuclear receptors LXR and THR. 
Luciferase reporter analysis of the mGlut5 promoter for regulation by nuclear receptors LXRα, LXRβ, THRα 
and THRβ. CV-1 cells were co-transfected with the proximal mouse Glut5 promoter (−1014/+3 bp) and 
expression plasmids for the different NRs in combination with equal amounts of heterodimeric partner RXRα. 
Y-axis indicates luciferase activity relative to LacZ and normalized to the basal hGLUT5 promoter activity. 
Ligand-dependent activation of LXR and THR was tested by addition of T09 (1 μM) or T3 (1 μM), respectively, 
at 24 h after transfection.
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In vivo regulation of Glut5 expression by LXR in mice. To investigate a potential role for LXR-mediated 
regulation in vivo, we determined the mRNA and protein levels of Glut5 in tissues of male C57BL/6J mice that 
were treated with T09 (30 mg/kg/d) supplemented in standard chow diet for 1, 7 or 14 days. As expected T09 
increased hepatic triglyceride levels but did not have a significant effect on food intake and total body weight 
(Fig. S5a–c). As a positive control for the effect of T09 treatment on LXR-mediated transcription we determined 
mRNA levels of sterol regulatory element-binding protein 1c (Srebp1c), a well-described LXR target gene32,33. 
Srebp1c mRNA levels were strongly increased upon T09 treatment in the small intestine (duodenum and jeju-
num) and liver after 1, 7 and 14 days of T09 treatment (Fig. 4a–d). In epididymal white adipose tissue (eWAT), 
there was also an increase in Srebp1c mRNA by T09 treatment, but this only reached significance after 14 days 
(Fig. 4h).
Glut5 expression was highest in the duodenum and both mRNA and protein levels were significantly increased 
after 7 days of treatment with T09 (Figs 4e, 5a). In jejunum Glut5 mRNA only showed a trend towards an increase 
but this was not statistically significant (Fig. 4f). Glut5 expression levels were low and undetectable in liver and 
skeletal muscle, respectively, and did not change upon T09 treatment (Fig. 4g, not shown). Interestingly, Glut5 
expression both, at the mRNA and protein level, was also increased in eWAT of mice treated with T09 for 14 days, 
showing a similar pattern as observed for Srebp1c (Figs 4h, 5b).
Discussion
Despite recent efforts in fructose research, many regulatory mechanisms involved in fructose absorption and 
metabolism, as well as the impact of dietary fructose in health and disease, have remained unclear. GLUT5 is 
indispensable for intestinal fructose absorption and, therefore, essential to absorb an important dietary compo-
nent of modern diets. However, regulatory pathways that modulate GLUT5 expression are not well understood.
In response to fructose, GLUT5 traffics to the apical cell membrane by the Ras-related protein in brain 11a 
(Rab11a), followed by fructose absorption by enterocytes. In the cytoplasm, fructose is phosphorylated by KHK, 
a step required for the increased expression of fructolytic genes, including GLUT534,35. Intracellular fructose or its 
metabolites in turn stimulate the transcription factor carbohydrate responsive element-binding protein (ChREBP, 
also known as MLX-interacting protein-like (MLXIPL)), which promotes the uptake and conversion of excess 
carbohydrate by regulating glycolytic, lipogenic and fructolytic genes, including Glut536. Recently, it was shown 
that the majority of ingested fructose is metabolized by the intestine, whereas only excess spills over to the liver37. 
In line with this, mice with an intestinal- but not hepatic ChREBP deficiency display fructose intolerance38.
Here we show that the human GLUT5 promoter is strongly and specifically induced by LXRα. LXRα is a 
member of the NR family of ligand-activated transcription factors and its natural ligands are oxysterols which 
are oxidized derivatives of cholesterol. The LXR subfamily consists of two closely related isoforms, LXRα and 
LXRβ (NR1H3 and NR1H2) that are highly conserved between humans and rodents. LXRα is restricted pre-
dominantly to tissues that are active in lipid metabolism, including liver, intestine and adipose tissue. In con-
trast, LXRβ is much more widely expressed and is found in almost every tissue examined. Physiologically, LXRs 
act as cholesterol sensors and promote the transcription of genes involved in cholesterol homeostasis including 
intestinal cholesterol absorption and reverse cholesterol transport. Besides their role in cholesterol homeostasis 
LXRs also regulate carbohydrate metabolism, for example through direct regulation of the bifunctional enzyme 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2/FBP2), which has a role in hepatic glycolysis and 
gluconeogenesis39.
LXRs modulate gene transcription by heterodimerising with the Retinoid X Receptor (RXR) and 
binding to direct repeat of the consensus hexanucleotide sequence AGGTCA with a spacing of 4 (DR4, 
AGGTCAnnnnAGGTCA), also termed LXRE in the promoters of target genes. We observed a specific induction 
of the human GLUT5 promoter by LXRα and this could be further stimulated by addition of ligand. In contrast, 
LXRβ was a much less potent activator of GLUT5 and could also not be further stimulated by ligand. It is gen-
erally believed that the LXR isoforms have largely overlapping target genes, however, isoform-specific functions 
have also been found. Activation of genes involved in Srebp1c-mediated hepatic de novo lipogenesis is mostly 
contributed to LXRα activation while target genes in peripheral tissues are regulated by both isoforms40. When 
we further characterized the regulation of the human GLUT5 promoter by LXR, we identified a DR4 type LXRE 
located at −429 to −374 bp upstream of the ATG start codon. Interestingly, this specific DR4 element in the 
human GLUT5 promoter was previously described to be regulated by THR. This interaction was first described 
by Matosin-Matekalo et al., who located a functional DR4 site in the human GLUT5 promoter sequence respon-
sible for THR regulation19. Our data is consistent with their finding and we also show that LXRα and THR can 
competitively bind this DR4 site. An interaction between LXR and THR on a DR4 element in promoters of target 
genes has previously been described for other genes, explaining extensive crosstalk between these receptors at 
different levels41–43. In addition to competitive DNA binding, there may also be other interactions between LXR 
and THR such as competition for cofactors.
Glut5 is also expressed in pre-adipocytes where it is involved in the adipogenesis, resulting in reduced adi-
posity in eWAT of Glut5−/− mice and potentially contributing to the increased (visceral) adiposity caused by 
high-fructose consumption44. Under normal conditions, the physiological relevance of peripheral fructose 
metabolism is thought to be limited since fructose is normally readily taken up and metabolized by the intestine, 
resulting in low systemic fructose levels45. Moreover, the rate-limiting enzyme KHK-C is absent or expressed at 
very low levels in adipocytes, so fructose metabolism is dependent on the inefficient KHK-A splice variant in adi-
pose tissue46. Nevertheless, deletion of KHK-A resulted in an exacerbated metabolic phenotype in mice receiving 
30% fructose via their drinking water, highlighting the relevance of peripheral fructose metabolism by KHK-A 
under conditions of excessive fructose consumption47. This supports the hypothesis that it is metabolically bene-
ficial to divert hepatic fructose metabolism by increasing fructose uptake in adipocytes.
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In mice we demonstrated that treatment with the synthetic LXR ligand T09 significantly stimulates Glut5 
expression in the small intestine and eWAT after 7 and 14 days of treatment, respectively. Importantly, this tran-
scriptional upregulation of Glut5 was accompanied by an induction of GLUT5 protein levels both in duodenum 
and eWAT after T09 treatment. In line with a direct activation of the Glut5 promoter by LXRα, genomic analysis 














































































































































Figure 4. Effect of LXR-activation by T0901317 treatment on Glut5 and Srebp1c expression in mice. mRNA 
levels of Srebp1c and Glut5 in (a,e) duodenum, (b,f) jejunum, (c,g) liver and (d,h) eWAT in wild-type mice 
treated for 1, 7 or 14 days with 0.015% T09 supplemented in their standard chow diet (n = 5–8, y-axis; 
normalized to 36B4 universal reference gene). Data are presented as boxplots (middle line, median; box, 25th–
75th percentiles; whiskers, 5th–95th percentiles).
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The fact that Glut5 in eWAT was only increased after 14 days of treatment could also point towards a mecha-
nistic pathway downstream of LXR activation, such as via regulation of ChREBP, which itself is an LXR target48. 
ChREBβ, but not α, was slightly increased in adipose tissue after 14 days T09 treatment. Intestinal ChREBα/β 
expression, however, was unchanged during LXR activation (Fig. S6). Besides, this delayed expression in adipose 
tissue was also observed for Srebp1c, which is only a direct target of LXR but not of ChREBP. To establish the 
potential ChREBP-dependent effects in response to LXR activation additional studies are needed. Finally, delayed 
induction in adipose tissue might also be explained by for example delayed accumulation of the ligand in this 
tissue.
LXR agonists have been extensively investigated for their therapeutic potential in a variety of diseases includ-
ing atherosclerosis, inflammatory diseases, diabetes and Alzheimer’s disease49. Several synthetic LXR ligands 
are being investigated in clinical trials50–52, however, their development has been challenged by adverse effects 
such as severe hepatic steatosis and hypertriglyceridemia53,54. To address this problem a new generation of highly 
potent and selective LXR modulators is being developed that separate the benefits of the LXR-agonists from 
their unwanted side effects. For example, LXRα-selective antagonists or inverse agonists might be efficacious 
in the treatment of NAFLD without affecting reverse cholesterol transport55. On the other hand LXRβ-selective 
agonists are potentially useful to improve cognition in Alzheimer’s disease while avoiding stimulation of hepatic 
lipogenesis by LXRα, the predominant isoform in the liver56. GLUT5 expression is increased in the intestine and 
in skeletal muscle of T2D patients but also in certain cancers that are highly dependent on fructose uptake and 
metabolism, providing an alternative route for energy delivery during insulin resistance or to match increased 
energy demand caused by uncontrolled proliferation, respectively28,29. As a ligand-activated transcription factor 
LXRα might provide novel pharmacologic strategies for the selective modulation of GLUT5 activity in the treat-
ment of metabolic disease as well as cancer.
Materials and Methods
Animals. Male mice of >99% C57BL/6J genetic background (Charles River, USA) between 8–12 wks of age 
were used in this study. Animals were housed in a light- and temperature-controlled facility (lights on from 7 a.m. 
to 7 p.m., 21 °C) with free access to water and standard chow (RMH-B, AB Diets). Animal experiments were per-
formed with the approval of the local Ethics Committee for Animal Experiments of the University of Groningen. 
All experiments were performed in accordance with relevant guidelines and regulations (including laboratory 
and biosafety regulations).
Animal experiments. Mice were randomized into four groups including three treatment groups and 
one control group. Mice were treated with the synthetic LXR ligand T0901317 (T09; Cayman chemical, USA; 
0.015%; ~30 mg/kg/day) added to their chow diet for either 1 day, 1 week or 2 weeks. The control group received 
non-supplemented chow diet. Mice were anesthetized with isoflurane and euthanized by cardiac puncture fol-
lowed by cervical dislocation. Tissues were collected and frozen in liquid nitrogen.











































Figure 5. Effect of LXR-activation by T09 treatment on Glut5 protein levels in mice. Representative western 
blot analysis and quantification of Glut5 and Gapdh protein levels in (a) duodenum and (b) eWAT in wild-type 
mice treated for 14 days with 0.015% T09 supplemented in their standard chow diet (n = 4–6). Western blot 
quantification is depicted as boxplots (middle line, median; box, 25th–75th percentiles; whiskers, 5th–95th 
percentiles).
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Cell culture. CV-1 (Monkey kidney fibroblast cell line) and Hek293 cells (human embryonic kidney cell 
line) were cultured at 37 °C and 5% CO2 in Dulbecco’s Modified Eagle (DMEM) GlutaMAXTM medium (Life 
Technologies, USA) with high D-glucose (4.5 g/L), pyruvate and supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) (Life Technologies, USA), and 1% penicillin and streptomycin (p/s) (Life Technologies, 
USA). Cells were grown till 80% confluence and split at least twice a week.
Plasmids, cloning and site-directed mutagenesis. Full length cDNAs for the murine nuclear receptors 
LXRα, LXRβ, RXRα, THRα and THRβ were cloned into the pcDNA3.1-V5H6 vector (Invitrogen, USA). The 
human GLUT5 promoter (−900 to +3 bp relative to the transcriptional start site (TSS) inserted in a reporter 
plasmid (pGL4-luc)) was obtained from SwitchGear Genomics (USA). Human GLUT5 promoter truncations 1–3 
(−783, −429 and −374 to +3 bp relative to TSS, respectively) were generated by digestion of the human GLUT5 
promoter using, respectively, restriction enzymes BglI; Acc65I and BsaI; PvuII, HindIII and Acc65I (Promega, 
USA) followed by subcloning into pGL4-luc or by ligation using Rapid DNA ligation kit (Roche, Germany). 
Site-directed point mutations were introduced into the human GLUT5 promoter by 2-step overlap-extension PCR 
using Expand High Fidelity PCR system (Roche, Germany) as described in literature57. Primers were designed 
to contain mutated nucleotides and restriction sites for SacI and HindIII using the human GLUT5 promoter 
construct as a template.
The mouse Glut5 promoter (−1014 to +3 bp) was generated by PCR using C57BL/6 mouse genomic DNA as 
a template followed by cloning into the pGL4-basic luciferase vector using the restriction sites NheI and HindIII 
(Promega, USA). All constructs were validated by Sanger sequencing (BaseClear, Leiden).
High-throughput NR promoter reporter screen. Promoters were tested for regulation by individual 
ligand-activated NR-members that heterodimerize with RXR (Table S1). For high-throughput screening, plas-
mids of NR/RXR heterodimers (15 ng NR + 15 ng RXR), promoter-reporters (30 ng) and internal controls (5 ng) 
pRL TK-Renilla (Promega, WI, USA) or pCMV-lacZ (Clontech CA, USA) were aliquoted in a volume of 10 μl/
well into 384-well plates (Corning, 3707) using a 96-head liquid handling robot (Packard Evolution). The empty 
pcDNA3.1/V5-HisA vector (Invitrogen) was used to equalize the total amount of DNA transfected in all condi-
tions. For reverse transfection, FuGENE HD (0.195 µl/well) and OptiMEM (4.805 µl/well) were mixed and 5 µl 
was added per well. After adding, the plate was gently shaken at RT and 35 µl of CV-1 cells (resuspended in phenol 
red-free DMEM medium with 10% charcoal-stripped serum) was added per well using a Titertek Multidrop 384 
automated HT cell dispenser, making up a total volume of 50 µl per well. Plates were covered with a breathable 
seal and shaken gently before returning them to the incubator. The next day, 5 µl of ligand (Table S1) or control 
medium was added per well and incubated for another 24 h. The third day, plates were analyzed for luciferase 
activity using a luminometer (Wallac 1420 VICTOR2™ V, Perkin Elmer).
Reporter assays. CV-1 cells were seeded in 48 wells plates and the medium was changed to DMEM 
GlutaMAXTM medium (Life Technologies, CA, USA) with high D-glucose (4.5 g/L), pyruvate and supple-
mented with 10% heat-inactivated charcoal-stripped FBS (Life Technologies, USA), and 1% antibiotics (p/s; Life 
Technologies, CA, USA) before transfection. CV1 cells were transiently transfected with plasmids containing 
promoter reporters (100 ng) and NR cDNAs (50 ng unless otherwise stated) in OptiMEM (Life Technologies, 
USA) using FuGENE® HD reagent (Promega, USA). The empty pcDNA3.1/V5-HisA vector (Invitrogen) was 
used to equalize the total amount of DNA transfected in all conditions. Renilla (3 ng, pRL TK-Renilla, Promega, 
USA) and LacZ (10 ng, pCMV-LacZ, Clontech, USA) were co-transfected in all experiments to normalize for 
variation in transfection efficiency. Figures are shown with LacZ as internal control unless otherwise stated. NR 
ligands were added 24 hours after transfection, and luciferase activity was determined 48 hours after transfection 
using a Dual-Luciferase Assay kit (Promega, USA) and measured using the SynergyH4 hybrid reader (BioTek, 
USA). Ligands used were T0901317 (1 μM T09, Cayman Chemical in DMSO), triiodothyronine (1 μM T3 in 
absolute ethanol, Sigma-Aldrich, USA) and 9-cis-Retinoic acid (1 μM 9cRA in DMSO, Sigma-Aldrich, USA), 
unless otherwise stated in the figure legend. Ligands were tested with the empty vector and showed no effects 
on luciferase signal in absence of their NR. In addition, vehicle solvents were tested and had no influence on 
the luciferase signal in these reporter experiments. The human GLUT5 promoter activity measured as luciferase 
signal is influenced by factors present in FBS and, therefore, stripped FBS is used in our luciferase reporter assays 
(Fig. S1). Results shown are representative for at least three independent experiments.
Gene expression analysis. RNA was isolated from the liver, skeletal muscle, WAT and the proximal (duo-
denum) and middle (jejunum) part of the small intestine of the mice. Total RNA was isolated using Trizol (Life 
Technologies, USA) and reverse transcribed into cDNA using M-MLV reverse transcriptase kit (Invitrogen) and 
random nanomer primers (Sigma-Aldrich, USA). For quantitative PCR (qPCR), cDNA was amplified using 
Hi-ROX SensiMix™ SYBR green (Bioline, London, UK) and StepOnePlus™ Real-Time PCR System (Applied 
Biosystems, CA, USA). Intron-spanning primers were used to prevent the amplification of genomic DNA (primer 
sequence in Table S2). Ribosomal protein RPLP (36B4) was used as a reference gene to normalize the data accord-
ing to the ∆∆Ct method.
Protein analysis. For immunoblot analysis, whole-cell lysates were obtained using M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific, USA) supplemented with Complete inhibitor cocktail tab-
let (Roche, Germany). Protein concentrations were quantified using the RC DC protein assay (Bio-Rad, USA). 
Protein samples were subjected to SDS-PAGE (4–15% gradient gels, Biorad, USA) and transferred to nitrocellu-
lose using Trans-Blot® TurboTM transfer system (Bio-Rad, USA). After blocking for 1 hour at room temperature 
(RT) in TBS containing 0.1% Tween and 2% milk powder, membranes were incubated overnight with primary 
antibodies at 4 °C. Primary antibodies used in this study are: anti-Glut5 (Millipore cat# 07-1406, 1:1000) and 
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anti-GAPDH (Calbiochem, Darmstadt, 1:5000). Antibodies were detected by incubating the blot with horserad-
ish peroxidase (HRP)-conjugated donkey anti-rabbit (Life science, NA934, 1:2500) or rabbit anti-mouse (Dako, 
p0260, 1:5000) IgG for 1 hour at RT. Protein bands were detected using ChemiDoc (Bio-Rad, USA) after incu-
bation with the SuperSignal West Pico Chemiluminescent Substrate System (Thermo Fisher Scientific, USA). 
GLUT5 levels in samples were calculated relative to GAPDH using Image lab 3.0 software (Bio-Rad Laboratories, 
USA).
Statistical analysis. GraphPad Prism 5.00 software package (GraphPad Software, USA) was used to per-
form statistical analysis. For reporter assays, a representative experiment is shown (n = 3) and significance was 
determined using a t-test when comparing two groups and a one-way ANOVA followed by a Tukey’s post-hoc 
test when comparing more groups. Significance in animal experiments was determined using the nonparametric 
Mann Whitney U-test when comparing two groups or the Kruskal-Wallis H-test when comparing more groups. 
The Dunns post-hoc test was performed after a significant Kruskal-Wallis test. All values are given as means ± SD 
unless stated otherwise. Significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001.
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